Traditional Chinese medicine beverage for protecting liver and reducing lipid

Abstract

The invention discloses a liver-protecting and lipid-lowering traditional Chinese medicine beverage, which comprises a beverage, the beverage comprises 18g of coffee and 8g of paraphlonia, and distilled water, and relates to the technical field of traditional Chinese medicine beverages. Coffee and paraphlonia are combined, so that homology of medicine and food is achieved, and the effect of effectively lowering lipid is achieved. According to the conventional lipid-lowering scheme used at present, statins are used, however, adverse reactions such as myalgia, myositis, new diabetes mellitus and abnormal liver function are likely to occur after the statins are taken for a long time, drug intervention standards are not met, however, by using the golden sophora japonica coffee, lipid can be effectively lowered while the dietary structure is adjusted, and almost no side effect exists; the product can be used for a long time and can reduce risk factors of hyperlipidemia. Coffee not only has a lipid-lowering effect, but also can reduce the total-factor death rate by reducing the heart rate through habitual intake of coffee, and high-quality paraphlonia and pure Yunnan small-grain coffee are selected as paraphlonia coffee, so that mellow and rich taste can be ensured, and patients can easily insist on taking the paraphlonia coffee.

Description

Technical Field

[0001] The invention relates to the technical field of traditional Chinese medicine beverages, in particular to a traditional Chinese medicine beverage for protecting liver and reducing lipids. Background Art

[0002] With the continuous improvement of material living standards, people tend to have an unhealthy diet with high fat, high sugar and high salt, and abnormal blood lipid levels are becoming more and more common. Hyperlipidemia has gradually become a common clinical disease, and the overall prevalence of adults can be as high as 35.6%. Hyperlipidemia is a chronic disease syndrome of abnormal systemic lipid metabolism caused by various reasons, which is manifested by elevated levels of total cholesterol, triglycerides and low-density lipoprotein in plasma or too low levels of high-density lipoprotein. At present, statins are commonly used in clinical practice to adjust the blood lipid levels of patients with hyperlipidemia, but due to the adverse reactions of such drugs and the fact that patients with mild hyperlipidemia do not meet the medication requirements, drug treatment has certain limitations. Compared with drug treatment, the use of medicine and food products has better safety and is not restricted by medication requirements. Its application range is wider and has good market development prospects. Coffee is warm in nature, bitter and sour in taste, and has the effects of refreshing the mind, strengthening the stomach and digesting food. The caffeine in coffee can stimulate metabolism and promote the oxidative decomposition of fatty acids; polyphenol compounds have antioxidant and anti-inflammatory effects, which can prevent and improve vascular endothelial inflammation; cafestol and caffeamide are believed to have the effect of regulating lipid metabolism and reducing blood lipid synthesis.

[0003] Sophora japonica is the dried flower and bud of Sophora japonica. Sophora japonica is a traditional Chinese medicine. It is slightly cold and bitter. It has the effects of clearing away heat and detoxification, diuresis, lactation, and digestion. Sophora japonica contains rutin and quercetin. Rutin has a vitamin P-like effect and has the effects of lowering blood lipids, anti-inflammatory, anti-allergic, diuretic, antispasmodic, and antitussive. Summary of the invention

[0004] The purpose of the present invention is to provide a Chinese medicinal beverage for protecting liver and reducing lipids. This product innovatively combines golden sophora japonica and coffee, and utilizes the effects of both on regulating lipid metabolism to achieve the clinical efficacy of lowering blood lipids and reduce the risk factors for hyperlipidemia. Medicine and food have the same origin, and there are almost no side effects, which makes this product more safe and can be used for a long time. It has a good preventive and conditioning effect on people with mild hyperlipidemia, and solves the problems raised in the above background technology.

[0005] To achieve the above-mentioned purpose, the present invention provides the following technical solution: a Chinese medicinal beverage for protecting liver and reducing lipids, including a beverage, wherein the beverage contains golden locust, coffee and distilled water, the coffee requires 18g, the golden locust requires 8g, and the distilled water requires 275ml, and the amount of the beverage used is increased or decreased according to the proportion.

[0006] A method for preparing a liver-protecting and lipid-lowering Chinese medicinal beverage, comprising:

[0007] Step S1: prepare 18g of golden acacia powder and 8g of coffee powder, add 275ml of distilled water and mix;

[0008] Step S2: placing the mixed solution into a vacuum distiller for distillation at 55° C.;

[0009] Step S3: distill until the solution is concentrated to 1 g / ml golden acacia coffee concentrate.

[0010] As a further solution of the present invention: a Chinese medicinal beverage for protecting liver and reducing lipids, the golden sophora is refined into golden sophora refined powder by freeze-crushing technology, and the coffee is made into coffee powder by cold extraction process.

[0011] Compared with the prior art, the present invention has the following beneficial effects:

[0012] This application innovatively combines golden locust and coffee, and uses the effects of both on regulating lipid metabolism to achieve the clinical efficacy of lowering blood lipids and reduce the risk factors for hyperlipidemia. Medicine and food have the same origin, and there are almost no side effects, which makes this product safer and can be used for a long time. It also has a good preventive and conditioning effect on people with mild hyperlipidemia;

[0013] This application combines coffee and golden locust, and the medicine and food are of the same origin, achieving the effect of effective lipid reduction. The conventional lipid-lowering scheme currently used is to use statins, but long-term use of statins is prone to adverse reactions such as myalgia, myositis, new-onset diabetes, and abnormal liver function, which limits the clinical application of drugs. At the same time, the current clinical use of statins requires LDL-C ≥ 4.1mmol / L, but many patients have a mild increase in LDL-C and do not meet the drug intervention standard. Such patients can only control blood lipids by adjusting the diet structure, but the use of golden locust coffee can effectively reduce lipids while adjusting the diet structure, and there are almost no side effects, and it can be used for a long time, which can reduce the risk factors for hyperlipidemia. Coffee not only has a lipid-lowering effect, but modern medical research shows that habitual intake of coffee can reduce all-cause mortality by lowering heart rate, and golden locust coffee uses high-quality golden locust and pure Yunnan small-grain coffee, which can ensure a mellow and rich taste, and is easy for patients to adhere to taking. BRIEF DESCRIPTION OF THE DRAWINGS

[0014] Figure 1 A Chinese medicinal beverage for protecting liver and reducing lipids according to the present invention;

[0015] Figure 2 This is a reference standard diagram of ASCVD in a liver-protecting and lipid-lowering Chinese medicinal beverage of the present invention;

[0016] Figure 3 A stratified table diagram of serum cholesterol levels in a liver-protecting and lipid-lowering Chinese medicinal beverage of the present invention;

[0017] Figure 4 A diagram of SREBP2 regulation in a liver-protecting and lipid-lowering Chinese medicinal beverage of the present invention;

[0018] Figure 5 A technical roadmap for a liver-protecting and lipid-lowering Chinese medicinal beverage of the present invention;

[0019] Figure 6 A nutritional table diagram of a liver-protecting and lipid-lowering Chinese medicinal beverage of the present invention;

[0020] Figure 7 This is a pathological section diagram of a Chinese medicinal beverage for protecting liver and reducing lipids according to the present invention;

[0021] Figure 8 This is a TG table diagram of a liver-protecting and lipid-lowering Chinese medicinal beverage of the present invention;

[0022] Fig. 9 This is a table diagram of HDL in a liver-protecting and lipid-lowering Chinese medicinal beverage of the present invention;

[0023] Fig.10 This is a table diagram of LDL in a liver-protecting and lipid-lowering Chinese medicinal beverage of the present invention;

[0024] Fig.11 This is a table of ALT in a liver-protecting and lipid-lowering Chinese medicinal beverage of the present invention;

[0025] Fig.12 This is a table diagram of AST in a liver-protecting and lipid-lowering Chinese medicinal beverage of the present invention;

[0026] Fig.13 This is a CREA table diagram of a liver-protecting and lipid-lowering Chinese medicinal beverage of the present invention;

[0027] Fig.14 This is a schematic diagram of target communication in a Chinese medicinal beverage for protecting liver and reducing lipids according to the present invention;

[0028] Fig.15 A protein interaction network diagram of a liver-protecting and lipid-lowering Chinese medicinal beverage of the present invention;

[0029] Fig.16 A network diagram of Chinese medicine-disease-target in a Chinese medicine beverage for protecting liver and reducing lipids according to the present invention;

[0030] Fig.17 The present invention provides a biological process analysis in a Chinese medicinal beverage for protecting liver and reducing lipids;

[0031] Fig.18 This is a KEGG pathway analysis diagram of a liver-protecting and lipid-lowering Chinese medicinal beverage of the present invention;

[0032] Fig.19 This is an expression diagram of AKT1_Quercetin in a liver-protecting and lipid-lowering Chinese medicinal beverage of the present invention;

[0033] Fig. 20 This is the expression diagram of EGFR_Kaempferol in a liver-protecting and lipid-lowering Chinese medicinal beverage of the present invention;

[0034] Fig.21 This is the expression diagram of SRC_Quercetin in a liver-protecting and lipid-lowering Chinese medicinal beverage of the present invention;

[0035] Fig. 22 This is a graph showing the expression of STAT3_Quercetin in a liver-protecting and lipid-lowering Chinese medicinal beverage of the present invention;

[0036] Fig.23 This is a graph showing the expression of TNF_Quercetin in a Chinese medicinal beverage for protecting liver and reducing lipids according to the present invention;

[0037] Fig.24 This is a medical imaging diagram of an experiment in a Chinese medicinal beverage for protecting liver and reducing lipids according to the present invention; DETAILED DESCRIPTION

[0038] The following will be combined with the drawings in the embodiments of the present invention to clearly and completely describe the technical solutions in the embodiments of the present invention. Obviously, the described embodiments are only part of the embodiments of the present invention, not all of the embodiments. Based on the embodiments of the present invention, all other embodiments obtained by ordinary technicians in this field without creative work are within the scope of protection of the present invention.

[0039] In the description of the present invention, it should be noted that, for those skilled in the art, the specific meanings of the above terms in the present invention can be understood in specific situations. The following describes an embodiment of the present invention based on its overall structure.

[0040] In an embodiment of the present invention, a Chinese medicinal beverage for protecting liver and reducing blood lipids includes a beverage, wherein the beverage contains golden locust, coffee and distilled water, wherein 18g of the coffee is required, 8g of the golden locust is required, and 275ml of the distilled water is required, and the amount of the beverage used is increased or decreased according to a proportion, the golden locust is refined into golden locust refined powder by freeze-crushing technology, and the coffee is made into coffee powder by cold extraction process.

[0041] A method for preparing a liver-protecting and lipid-lowering Chinese medicinal beverage, comprising:

[0042] Step S1: prepare 18g of golden acacia powder and 8g of coffee powder, add 275ml of distilled water and mix;

[0043] Step S2: placing the mixed solution into a vacuum distiller for distillation at 55° C.;

[0044] Step S3: distill until the solution is concentrated to 1 g / ml golden acacia coffee concentrate.

[0045] This application innovatively combines golden sophora and coffee, and utilizes the effects of both on regulating lipid metabolism to achieve the clinical efficacy of lowering blood lipids and reduce the risk factors for hyperlipidemia. Medicine and food have the same origin, and there are almost no side effects, which makes this product safer and can be used for a long time, and has a good preventive and conditioning effect on people with mild hyperlipidemia.

[0046] This application focuses on the intervention of mild hyperlipidemia, and preliminarily explores its mechanism of action through animal experiments, exploring the clinical effectiveness and safety of golden locust coffee. The expected results are expected to develop a health food that is both medicinal and edible for mild hyperlipidemia.

[0047] Hyperlipidemia, also known as hyperlipoproteinemia, is a chronic metabolic disease of fat metabolism disorder. In recent years, the prevalence of dyslipidemia in adults in my country has remained at a high level. Dyslipidemia is the key pathological basis of many cardiovascular and cerebrovascular diseases. The most common clinical consequence is the increased risk of atherosclerotic cardiovascular disease (ASCVD). At present, common drugs for improving blood lipids are divided into drugs that mainly lower cholesterol and drugs that mainly lower triglycerides (TG) according to their main effects. The main cholesterol-lowering drugs include statins, cholesterol absorption inhibitors, proprotein convertase subtilisin 9 inhibitors, probucol, and bile acid chelators; the main triglyceride-lowering drugs include fibrates, niacin, high-purity ω-3 fatty acids, etc. Long-term use of such drugs can lead to many side effects such as myositis, immune system diseases, and new-onset diabetes, which limits the clinical application of drugs. At present, patients with mild hyperlipidemia do not meet the standards for drug intervention, so there is no good drug or health care drug for intervention. It is imperative to find and develop a drug-food homologous product with few side effects and can improve mild hyperlipidemia. Hyperlipidemia, also known as hyperlipoproteinemia, refers to the presence of triglyceride (TC) or cholesterol (TG), elevated low-density lipoprotein cholesterol (LDL-C) levels, and decreased high-density lipoprotein cholesterol (HDL-C) levels in the human body, resulting in a chronic metabolic disease of fat metabolism disorders.

[0048] See also Figure 2 and Figure 3The "Guidelines for Blood Lipid Management in China (2023)" pointed out that the prevalence of dyslipidemia in adults in my country has remained at a high level in recent years, with the total prevalence of dyslipidemia in adults reaching 35.6%, which is still higher than the prevalence of dyslipidemia in the national survey in 2015; among them, high TC blood (TC≥

[0049] The age-standardized prevalence of LDL-C ≥ 4.2mmol / L in 2018 increased by nearly 100% (from 4.9% to 8.2%). The prevalence of high LDL-C also continued to rise. In 2018, the proportion of adults with LDL-C ≥ 4.1mmol / L was 8.0%, while in 2010 and 2015, the proportions of adults with LDL-C ≥ 4.1mmol / L were 5.6% and 7.2%, respectively. A research report published in Nature magazine in 2020, covering 200 countries around the world, showed that in 1980, the average levels of TC and non-high-density lipoprotein cholesterol (non-HDL-C) in Chinese adults were among the lowest in the world, significantly lower than those in Western countries; in 2018, the average levels of TC and non-HDL-C in Chinese adults reached or exceeded the average levels of some Western countries.

[0050] Dyslipidemia is the key pathological basis of cardiovascular and cerebrovascular diseases, and there is still a lack of effective health care and prevention methods. The most common clinical consequence of dyslipidemia is an increased risk of atherosclerotic cardiovascular disease (ASCVD), which is associated with increased TC and LDL-C, triglycerides (TG) and lipoprotein (a), and decreased HDL-C. Evidence from epidemiological, genetic and clinical intervention studies has fully confirmed that LDL-C is a pathogenic risk factor for ASCVD. According to estimates by the World Health Organization, more than one-third of deaths caused by ischemic heart disease or ischemic stroke can be attributed to dyslipidemia. In 2019, approximately 4.4 million deaths and approximately 98.62 million disability-adjusted life years were caused by elevated plasma LDL-C levels. In June 2022, the American Lipid Society released the "NLA2022 New Definition and Key Considerations for Reducing the Risk of ASCVD in Patients with Statin Intolerance", pointing out that LDL-C is an important pathogenic risk factor and is closely related to ASCVD. Therefore, lowering LDL-C is the primary intervention target for the prevention and treatment of ASCVD. In addition, non-high-density lipoprotein cholesterol (NonHDL-C), including LDL-C and very low-density lipoprotein cholesterol (VLDL-C), can also be used to assess the risk of cardiovascular events and is a secondary intervention target for lipid-lowering therapy. Therefore, timely intervention in patients with dyslipidemia can reduce the occurrence of adverse cardiovascular events.

[0051] See also Fig.14, the intersection of the two targets was taken using R language and a Venn diagram was drawn, resulting in 152 intersection targets. The intersection targets were submitted to the STRING database (https: / / string-db.org) to construct a protein interaction network, the species was selected as "Homosapiens", and the target association confidence was set to 0.70 to obtain the PPI network relationship. There were 152 nodes, 489 edges, and an average degree of freedom of 6.43 in the network. The TSV file was imported into Cytoscape3.7.2 software and sorted by degree value. The top 5 targets were considered key targets.

[0052]

[0053] The interaction relationship between traditional Chinese medicine, compounds, diseases and targets was visualized using Cytoscape software to obtain the traditional Chinese medicine-disease-target interaction network, and the network was topologically analyzed. The compounds with the top five degree values ​​were taken as key compounds, among which green and yellow diamonds were drugs, green and yellow circles were compounds, red diamonds were diseases, and red circles were common targets of drugs and diseases. The results are shown in the following table and figure

[0054]

[0055] As other embodiments of the present invention: please refer to Fig.17, the common targets of drugs and diseases were imported into DAVID Bioinformatics Resources 6.8 (https: / / david.ncifcrf.gov / home.jsp) to perform GO biological process (biological process, BP), cell component (cell component, CC) enrichment, molecular function (molecular function, MF), enrichment conditions were PvalueCutoff = 0.05 and QvalueCutoff = 0.05, and the rest were defaulted to the original settings. Through analysis, it was found that 2192 GO entries were enriched. There are 61 cellular components, mainly located in the plasma membrane, nuclear protoplasm, intracellular membrane-bound organelles, RNA polymerase I transcription factor complex, flavonoid-1 granule lumen, cytoplasm, cytoplasmic perinuclear region, caveolae, chromatin and extracellular region; 503 biological processes, mainly regulating and participating in glucose homeostasis, positive regulation of MAP kinase activity, hormone-mediated signaling pathways, negative regulation of apoptosis, response to exogenous stimuli, negative regulation of inflammatory response, intracellular receptor signaling pathways, positive regulation of RNA polymerase Il promoter transcription, positive regulation of RNA polymerase I promoter pri-miRNA transcription and positive regulation of ERK1 and ERK2 cascades; 135 molecular functions, mainly manifested in RNA polymerase II transcription factor activity, ligand-activated sequence-specific DNA binding enzyme binding, protein-bound steroid binding, heme binding, steroid hormone receptor activity, protein serine / threonine / tyrosine kinase activity, sequence-specific DNA binding, zinc ion binding and insulin receptor substrate binding regulation. The top 10 enrichment items with significant enrichment were selected, and the GO analysis bubble chart was drawn using the Microbiological Information Platform (http: / / www.bioinformatics.com.cn / ) according to the P value, Q value and number of genes enriched in each item. The horizontal axis represents the number of targets, the left side represents BP, CC, and MF, and the color represents the P value. The smaller the P value, the more red the color tends to be, and the larger the P value, the more blue the color tends to be.

[0056] As other embodiments of the present invention: please refer to Fig.18, the drug-disease common targets were subjected to KEGG pathway enrichment analysis, and the drug-disease common targets were imported into DAVID Bioinformatics Resources 6.8 (https: / / david.ncifcrf.gov / home.jsp) targets for KEGG pathway enrichment analysis. The items with a corrected P value of <0.05 were screened, and a total of 157 signal pathways were enriched. The top 20 enrichment items with enrichment significance were selected, and the results were visualized and analyzed using the microbial information platform based on the P value, Q value and number of genes enriched on each item. The horizontal axis represents the number of enriched genes, the left side represents the pathway name, and the color represents the P value. The smaller the P value, the more the color tends to red, and the larger the P value, the more the color tends to blue. Mainly enriched in cancer pathways, endocrine resistance, chemical carcinogen-receptor activation, prolactin signaling pathway lipids and atherosclerosis, diabetic complications AGE-RAGE signaling, fluid shear stress and atherosclerosis, insulin resistance, EGFR tyrosine kinase inhibitor resistance, proteoglycans in tumors, relaxin signaling pathway, PPAR signaling pathway, estrogen signaling pathway, ErbB signaling pathway, Kaposi's sarcoma-associated herpes virus infection, Th17 cell differentiation, HIF-1 signaling pathway, focal adhesion, diabetic cardiomyopathy and VEGF signaling pathway.

[0057] As other embodiments of the present invention: please refer to Figure 19-Figure 23 , determine the compound name, molecular weight and 3D structure of the active ingredient from the PubChem database, and then download the 3D structure corresponding to the active ingredient from the RCSBPDB database (http: / / www.rcsb.org / ). Then use AutoDock software to prepare the ligands and proteins required for molecular docking. For the target protein, its crystal structure removes water molecules, adds hydrogen, modifies amino acids, optimizes energy and adjusts force field parameters, and then satisfies the low-energy conformation of the ligand structure. Finally, the 5 key target structures and 5 key active ingredient structures obtained above are molecularly docked, and their Affinity (kcal / mol) values ​​represent the binding ability of the two. The lower the binding ability, the more stable the ligand-receptor binding. Finally, use DiscoveryStudio to analyze and observe the docking results, select the 5 compounds with the best docking binding energy for each target protein, and draw a graph for analysis.

[0058]

[0059]

[0060] Other embodiments of the present invention: According to the treatment plan proposed in the "Guidelines for the Management of Blood Lipids in China (2023)", the commonly used lipid-lowering drugs are statins and proprotein convertase subtilisin / kexin9 (PCSK9) inhibitors. Statins are the cornerstone drugs for the treatment of dyslipidemia. There is evidence that statins can reduce ASCVD events, CV mortality and all-cause mortality in secondary prevention and primary prevention populations. At present, the statins developed by world medical technology mainly include 6 types, but the most widely used in clinical practice, and the four types of drugs with the best therapeutic effects are atorvastatin, lovastatin, pitavastatin and simvastatin. By around 2002, the World Medical Organization had developed a new generation of statins, ZD4522 (rosuvastatin). A large number of clinical experiments have shown that this statin plays a very important role in lowering lipids in patients. Even without the assistance of other drugs, the lipid-lowering effect of simply using rosuvastatin to treat patients is far superior to other statins. Therefore, this drug is called the "king statin" of statins. The main mechanism of action of statins is that it is a reductase inhibitor (HMG-CoA). With the help of this reductase inhibitor, acetyl coenzyme can be effectively catalyzed to synthesize mevalonate. It is the key enzyme for the synthesis of mevalonate in the human body, and mevalonate is the substrate for the synthesis of cholesterol in the human body. Therefore, by constructing an active competitive environment for reductase in the human body, the synthesis of endogenous cholesterol in the human body is effectively reduced, and the cholesterol concentration in the plasma and tissue cells in the human body is reduced. At the same time, it can also effectively increase the dependence of cholesterol concentration on low-density lipoprotein, and by accelerating the decomposition of low-density lipoprotein, the synthesis of very low-density lipoprotein is gradually reduced, thereby reducing the overall level of low-density lipoprotein in the human body. At the same time, related studies have found that statins inhibit cholesterol synthesis, reduce the cholesterol concentration in liver cells, promote the activation of transcription factor SREBP-2, and then upregulate the expression of LDLR and PCSK9 genes. Combined with the above analysis, statins inhibit cholesterol synthesis in the human body, which can reduce the total cholesterol (TC) in the human body by 30% to 40%, and can also reduce the low-density lipoprotein cholesterol (LDL-C) in the human body by 35% to 45%. Through comparative studies, it was found that rosuvastatin has a stronger lipid-lowering effect. The use of this type of statin can reduce the low-density lipoprotein cholesterol in the human body by 55% to 65%, so it is understandable to call it the "king statin."

[0061] However, relevant studies have found that some patients may be intolerant to statins. According to the results of multiple clinical trials and systematic reviews, the prevalence of statin intolerance (partial or complete) is approximately 5% to 30% due to different characteristics of the study population. Usually, muscle symptoms of statin intolerance are not accompanied by elevated creatine kinase (CK). Myopathy associated with statin therapy, defined as unexplained muscle pain or muscle weakness accompanied by CK greater than 10 times the upper limit of normal, is relatively rare, with an annual incidence of approximately 1 / 10,000. Rhabdomyolysis is even rarer, with an annual incidence of approximately 1 / 100,000. It can be life-threatening, but is usually reversible when discovered early. In addition to skeletal muscle-related symptoms, other symptoms or signs associated with statin therapy include elevated transaminases, worsening blood sugar, and rare disturbances of consciousness and memory loss. In addition, adverse reactions such as autoimmune antibodies, new-onset diabetes, and abnormal liver function limit the clinical application of the drug.

[0062] PCSK9 is synthesized in liver cells and can be secreted into plasma. After returning to the liver through the blood circulation, it binds to the low-density lipoprotein receptor (LDLR) on the surface of liver cells and then transports LDLR to lysosomes for degradation. As a result, the number of LDLR receptors in liver cells decreases, and the body's ability to remove cholesterol through LDLR is weakened, which ultimately leads to an increase in the level of low-density lipoprotein cholesterol (LDL-C) in plasma, thereby causing atherosclerosis and cardiovascular disease. Common PCSK9 inhibitor drugs are divided into three categories: monoclonal antibodies or antibody-mimicking proteins: ① Directly inhibit the binding of PCSK9 protein to LDL-R; ② Antisense oligonucleotides or small interfering RNA (siRNA): Inhibit PCSK9 transcription and synthesis through gene silencing; ③ Low molecular weight peptides acting on the catalytic site of PCSK9 protein: These peptides can bind to the catalytic site of PCSK9 protein to cause conformational changes, thereby affecting the binding of PCSK9 protein to LDL-R to achieve the effect of lipid-lowering. The "2023 China Lipid Management Guidelines" recommends that PCSK9 inhibitors should be mainly used in the following three situations: ① For those who still cannot reach the target LDL-C with moderate-intensity statins combined with cholesterol absorption inhibitors, PCSK9 inhibitors should be used in combination (I, A); ② For ultra-high-risk patients with high baseline LDL-C, statins combined with PCSK9 inhibitors can be considered directly (IIa, A); ③ Patients with familial hypercholesterolemia should choose single or combined LDL-C-lowering drugs, including statins, cholesterol absorption inhibitors, PCSK9 inhibitors, etc. (I, A) according to the needs of LDL-C target and individual tolerance. Taking the currently commonly used iloumab as an example, the method of use is subcutaneous injection, but it is an invasive operation and will produce local reactions. At the same time, the lipid-lowering speed of iloumab is faster, and it is easy to produce low LDL-C syndrome. In addition, PCSK9 inhibitors can also cause adverse reactions such as nasopharyngitis, muscle pain or muscle weakness, neurocognitive disorders, and injection site reactions may manifest as redness, swelling, pain, nodules, itching, blisters, erosions, breakages, or pigmentation. Studies based on real-world data have shown that PCSK9 inhibitors have milder adverse reactions than other drugs.

[0063] In addition, there are other drugs that can improve blood lipids. Common clinical drugs include ezetimibe, bile acid sequestrants, bempedoic acid, and fibrates. They achieve lipid-lowering goals through different mechanisms and can also reduce cardiovascular risk events. At present, the first siRNA drug for lowering cholesterol, Inclisiran, has gradually come out. It is a synthetic long-acting PCSK9 double-stranded small interfering RNA (PCSK 9 siRNA) that can specifically block PCSK9 transcription in the liver and increase the number of low-density lipoprotein receptors on the liver cell membrane, thereby reducing circulating LDL-C. At present, Inclisiran (ALN-PCSsc) has been authorized by the US Food and Drug Administration (FDA) and the European Medicines Agency (EMA). It has significant efficacy in lipid-lowering and may become a treatment method to replace PCSK9 monoclonal antibodies. However, it is expensive and has not yet been introduced on a large scale in China, so the clinical observation of this drug in China needs further exploration.

[0064] As other embodiments of the present invention: Although traditional Chinese medicine does not have the name "dyslipidemia", the recognition of dyslipidemia and related pathological changes has a long history. Fat turbidity in Chinese medicine is similar to "dyslipidemia" in Western medicine. Dyslipidemia can be classified into the categories of "phlegm and fluid", "obesity", "blood stasis", "dampness", "vertigo" and so on in Chinese medicine. Its pathogenic organs mainly involve spleen, kidney and liver, and the pathological mechanism is mainly "deficiency of the root and excess of the side", with deficiency of qi, blood, yin and yang as the root, phlegm turbidity and blood stasis as the side. The pathological state of this disease is mostly summarized by "cream", "fat" and "turbidity". "Lingshu·Defense Qi Disorder" says: "People have fat, cream and meat." It is also said: "The cream has more qi, the more qi is hot, and the hot is cold-resistant." Cream fat, as a nutrient for the human body, is produced from food and water, digested and absorbed in the spleen and stomach, and transferred by the spleen qi. The clear ones rise to the lungs, and the lung qi is released and descended like the irrigation of fog and dew, nourishing the whole body. "Lingshu·Five-Stuffed Pathogenic Intestines" says: "The body fluids of the five grains are combined to form fat, which penetrates into the bone cavity, nourishes the brain and flows down to the thigh groin", which reflects the characteristics that fat comes from the essence of water and grain, is transformed by body fluid, and flows through the body with blood to maintain the normal life activities of the human body. Modern people are fond of eating fat, sweet and greasy food, are more static and less active, and the Qi is not smooth, the liver is not smooth, and the spleen and stomach are not functioning properly. "Fat" accumulates in the middle burner, and the spleen cannot be transferred, overflowing in the veins from clear to turbid, forming fat turbidity. "Suwen·General Evaluation of Deficiency and Reality" says: "Sweet and fat nobles are the disease of fat. Blockage, closure, and lack of communication between the upper and lower parts are the disease of worry", and hyperlipidemia is more common in rich families. With the development of society and the improvement of people's living standards, the intake of fat, sweet and greasy food has greatly increased, which gathers in the body to form "fat turbidity", affecting the operation of Qi. Turbidity is sticky, and when it enters the blood vessels and wraps with blood, it is easy to deposit and stagnate. "Lingshu·Yin Yang Qing Zhu" says: "The turbid is the qi astringent", so it causes poor blood circulation, blood vessels are not smooth, and a state of stasis is formed. "If the blood is not smooth, it will become water", and phlegm and dampness are generated. "Zheng Yin Mai Zhi·Tan Zheng Lun" says: "When the body fluid is turbid, phlegm is generated instead of blood", and "Jing Yue Quan Shu" also says: "When the qi and blood are turbid and the body fluid is not clear, it will be fumigated and aggregated and become phlegm", which reflects the characteristics that abnormal blood lipids can continue to produce pathological products such as phlegm turbidity and blood stasis. Professor Fu Changgeng believes that the spleen and stomach are the foundation of the acquired constitution and the source of fat turbidity. The overflow and retention of fat turbidity in the blood vessels are closely related to abnormal spleen and stomach function; in addition, the liver is responsible for regulating the qi of the whole body, and the failure of liver qi to dredge can also cause fat turbidity to overflow and stagnate in the belt meridian. The etiology and pathogenesis of dyslipidemia are "liver failure to dredge and spleen and stomach heat accumulation".

[0065] Modern doctors have considered the TCM treatment of hyperlipidemia from multiple angles. The fundamental pathogenesis is the disorder of the rise and fall of the spleen and stomach in the middle jiao, and the blockage of phlegm and blood stasis. In clinical practice, the treatment methods are to strengthen the spleen and stomach, relieve phlegm and turbidity, promote the flow of qi, and restore the rise and fall. At the same time, according to the different constitutions of patients and the different proportions of different pathogenesis, hyperlipidemia is clinically classified into phlegm and dampness, blood stasis, liver depression and spleen deficiency, and spleen and kidney yang deficiency. According to this classification, many corresponding treatment methods have been produced. When treating hyperlipidemia, Professor Yao Kuiwu is good at using Baizhu and Zexie, Bupleurum and Astragalus, Chuanxiong and Atractylodes, etc., which embodies the characteristics of the medication of cold and heat, coordination of rise and fall, and consideration of qi and blood, and the clinical treatment effect is very good. Wang Shoufu is good at using Shenling Baizhu San and Erchen Decoction as the basic prescription to treat hyperlipidemia caused by phlegm and dampness, with significant clinical effect. Professor Li Jun advocates the treatment of phlegm and blood stasis in the treatment of hyperlipidemia. He clinically uses Banxia Baizhu Tianma Decoction combined with Taohong Siwu Decoction for treatment. Wang Jingjing used a self-made prescription for soothing the liver and strengthening the spleen to treat patients with liver depression and spleen deficiency in hyperlipidemia. The efficacy of aspirin enteric-coated tablets in treating patients with liver depression and spleen deficiency was better. Wang Yijian and others believed that the main symptom of elderly hyperlipidemia was spleen and kidney yang deficiency. Through research, it was found that Jinkui Shenqi Pills combined with Xuezhikang Capsules can effectively treat spleen and kidney yang deficiency in elderly hyperlipidemia and promote blood lipid decomposition. Traditional Chinese medicine treats this disease by resolving phlegm and lowering turbidity, promoting blood circulation and removing blood stasis. Previous studies have shown that coffee and golden sophora japonica, which are both medicinal and edible foods, have a good lipid-lowering effect because they are rich in effective substances such as caffeine and troxerutin. However, there is a lack of high-level evidence for its clinical effectiveness, and its mechanism of action is still in the theoretical prediction stage, which needs further exploration.

[0066] In short, Chinese medicine has unique advantages in the prevention and treatment of hyperlipidemia. Sophora japonica is a traditional Chinese medicine, and its active ingredient rutin has the effect of lowering blood lipids. Coffee is slightly bitter, astringent, and flat, and has the effects of refreshing, diuresis, and stomachic. It can regulate the qi through stomachic, and at the same time, it can promote water excretion to achieve the effect of removing dampness and reduce the risk factors of hyperlipidemia. At the same time, through previous studies, it has been proved that golden sophora coffee has a good lipid-lowering effect. Its medicinal properties are mild and it can be eaten as a daily food. It is a unique lipid-lowering Chinese medicine program.

[0067] As other embodiments of the present invention: golden hamsters were used as research objects, a hyperlipidemia mouse model was constructed, and the changes in TC, TG, LDL-C, AST, ALT, CR, and CK in the golden locust coffee group and the atorvastatin group were observed. HE staining was used to observe the liver tissue and aorta, and the blood lipid compliance rate and liver and kidney function indicators before and after oral administration of golden locust coffee and statins were explored, and the safety of the two was compared.

[0068] Golden hamsters were used as the research subjects, and a hyperlipidemia mouse model was constructed. The changes in TC, TG, LDL-C, AST, ALT, PCSK9mRNA, SEREBP2 protein expression levels, and LDLRmRNA expression levels in the golden locust coffee group and pitavastatin group were observed. This study aimed to explore whether golden locust coffee can reduce the expression of PCSK9 protein in the liver of hyperlipidemia golden hamsters, increase the expression of LDLR protein, alleviate lipid metabolism disorders through the SREBP2-PCSK9 signaling pathway, and thus reduce the serum lipid content of hyperlipidemia model golden hamsters.

[0069] Through a series of studies, it has been proven from the whole animal and patient levels that golden locust coffee can effectively improve hyperlipidemia. Its mechanism is to inhibit the expression of SREBP2 protein in hepatocytes, reduce the net content of PCSK9 protein, and thus inhibit the process of LDLR transporting LDLC to achieve the lipid-lowering effect. Therefore, this application conducts animal experiments, which adopt the male golden hamster hyperlipidemia model and the positive drug control research method.

[0070] As other embodiments of the present invention: please refer to Figure 4 , the preliminary study of this application found that caffeine and its derivatives reduce the potential mechanism of cardiovascular disease risk by reducing PCSK9 levels. Not only that, this mechanism also involves the regulation of SREBP2. This application uses caffeine to treat hepatocytes to increase the concentration of ERCa2+. Excessive ERCa2+ leads to increased peptide binding ability and chaperone activity of ER-resident GRP78. As a result, the ER-resident GRP78-SREBP2 complex has enhanced stability. The failure of SREBP2 to quickly exit the ER leads to a net decrease in the expression of lipid regulatory genes (including PCSK9, SREBP2 and PCSK9). As the outflow of new PCSK9 decreases, the half-life and abundance of LDLR on the cell surface increase, resulting in a net increase in LDLc clearance.

[0071] As other embodiments of the present invention: please refer to Figure 5 , this application includes

[0072] Experimental subjects and experimental conditions: Golden hamsters, male, 6-8 weeks old, weighing 90-120 g, were purchased from Beijing Weitonglihua Experimental Animal Technology Co., Ltd. Golden hamsters were raised in the Animal Experiment Center of Beijing University of Chinese Medicine in an SPF-grade free drinking water environment, with an ambient temperature of 23±2℃, a relative humidity of 55±10%, 12 h of light per day, and a day-night cycle.

[0073] Experimental feeding conditions: High-fat diet D12492 was purchased from Hebei Gaide Biotechnology Co., Ltd. Atorvastatin calcium was purchased from Pfizer Pharmaceuticals and was prepared with distilled water to the required concentration. Serum triglyceride (TG), total cholesterol (TC), low-density lipoprotein-cholesterol (LDL-C), and high-density lipoprotein-cholesterol (HDL-C) assay kits were purchased from Biosino Biopharmaceuticals Co., Ltd.

[0074] Sample conditions: SPF-grade 6-8-week-old male golden hamsters were fed with high-fat diet (D12492) or basic diet for 4 weeks, and then 5 hamsters were randomly selected from each group. The blood lipid level was detected by biochemical method to evaluate the effect of hyperlipidemia model preparation.

[0075] Grouping: The golden hamsters fed with basic feed were used as blank control group, and the golden hamsters with successful modeling were randomly divided into blank group, hyperlipidemia model group, golden locust coffee group and atorvastatin calcium group, with 10 in each group. Among them, the blank control group and the model group were given normal saline gavage (1mL / 100g / d); golden locust coffee was dissolved in an equal volume of normal saline for gavage; the atorvastatin group was given atorvastatin calcium 1.8mg / kg / d dissolved in an equal volume of normal saline, and the indicators were tested after 8 weeks of intervention.

[0076] Detection indicators

[0077] a) General Condition

[0078] Observe the general condition of the animals, record the amount of food given and the amount of food left over. Weigh the body weight, abdominal circumference and activity tolerance of the golden hamsters at the 1st, 2nd, 3rd and 4th week.

[0079] b) Oil red staining

[0080] Oil red O staining was used to evaluate the positive staining ratio of the liver, aorta (gross oil red), and aortic root sinus.

[0081] c) Blood lipid test

[0082] See also Figure 6After modeling and the second week of drug administration, the hamsters were fasted for 12 hours but not water, and then anesthetized with ether. 800 μL of blood was collected from the orbital vein with a 0.5 mm capillary tube. After standing on ice for 1-2 hours, the blood was centrifuged at 3000 r / min for 15 minutes at 4°C, and the supernatant was greater than or equal to 150 uL. The serum total cholesterol (TC), triglycerides (TG), low-density lipoprotein cholesterol (LDL-C) and high-density lipoprotein cholesterol (HDL-C) levels were detected with an automatic biochemical analyzer.

[0083] d) Related indicator detection

[0084] SEREBP2-PCSK9 pathway detection:

[0085] Western blotting detection: PCSK9 protein expression;

[0086] ·RT-qPCR method: Detect LDLR and PCSK9 mRNA in liver tissue.

[0087] Experimental results: Please refer to Figure 7 This application conducts a preliminary experimental study on the treatment of hyperlipidemia in golden hamsters with golden locust coffee. Golden locust coffee can improve the lipid metabolism of golden hamsters, reduce blood lipid levels, and is safe to take without adverse reactions. Figure 1 , Table 1-Table 4) This also confirms the effectiveness of golden locust coffee in intervening hyperlipidemia.

[0088] Analysis results: See Figure 8-Figure 13 The lipid-lowering mechanism of golden locust coffee is similar to that of PCSK9 inhibitors. Its specific pathway needs further study, but it can be taken orally, which greatly reduces the pain of patients. Its lipid-lowering speed is relatively gentle, which is suitable for patients with mildly elevated LDL-C. While enjoying the delicious coffee, it also has a lipid-lowering effect. The active ingredient in golden locust is rutin. This application uses the advanced freezing and crushing technology that is being patented for processing. The obtained golden locust refined powder has small particles. More than 93.71% of the golden locust refined powder particles have a diameter of <100μm. The dissolution rate of rutin is accelerated by more than 10 times, and the dissolution rate is significantly improved. The production of coffee adopts the cold extraction process. Cold brew coffee is extracted from coffee beans at -40℃ vacuum freezing, and then the coffee liquid is frozen and the ice is removed by sublimation to obtain instant coffee. Ultra-low temperature freezing can preserve the flavor and taste of coffee intact, and can lock in the nutrients of coffee itself. The coffee produced in this way has a rich aroma and a pure taste.

[0089] See also Fig.24This application also conducted an experimental control, which included a blank group, a model group, a low-dose golden locust coffee group, and a normal-dose golden locust coffee group. It can be seen from the figure that in the abdominal B-ultrasound image of the golden hamsters that took the normal-dose golden locust coffee, there were some abnormal tissues in the liver position compared with the blank group and the model group, while the liver area of ​​the golden hamsters that took the low-dose and normal-dose golden locust coffee recovered.

[0090] As other embodiments of the present invention: For patients with hyperlipidemia and high-risk groups, not only medication and food intervention should be carried out, but also improvement should be made in lifestyle. We advocate that patients should maintain a healthy lifestyle while taking golden locust coffee, including diet management, moderate exercise, smoking cessation and alcohol restriction, and a calm mood. Control blood lipids. Patients should try to avoid consuming high-fat foods, such as animal offal, cream, egg yolk, fish roe, etc. They should eat more low-fat foods such as vegetables, fruits, beans, and coarse grains. For children and adolescents, dietary intervention should not only improve dyslipidemia, but also ensure sufficient nutritional intake without affecting their growth and development. Appropriate exercise can help patients control their weight and enhance cardiopulmonary function. Patients with hyperlipidemia can do aerobic exercises such as jogging and swimming to lose weight, which helps to relieve hyperlipidemia. Smoking and excessive drinking will have a negative impact on blood lipid levels. Harmful components such as nicotine and carbon monoxide in tobacco will increase the levels of triglycerides and total cholesterol in the blood; ethanol will promote the synthesis of triglycerides and stimulate the release of fatty acids from adipose tissue, causing an increase in the synthesis of triglycerides in the liver. Therefore, patients with hyperlipidemia should quit smoking and limit their alcohol intake. Mental status has an important impact on human health. Chinese medicine believes that depression and discomfort will affect the release of liver qi in the long run, leading to qi stagnation and poor blood circulation, which may cause elevated blood lipids. Therefore, patients with hyperlipidemia should keep a calm mood and avoid huge emotional fluctuations and excessive tension.

[0091] As other embodiments of the present invention: Among the traditional Chinese medicines that can be used as both medicine and food, it was found through preliminary reference to relevant data that the lipid-lowering effects of coffee and Sophora japonica are particularly prominent.

[0092] Coffee (Coffe asp.) is a plant of the Rubiaceae family, native to north-central Africa, and now widely planted in Latin America, Africa, and the Asia-Pacific region. There are many varieties of coffee, up to more than 90, which are divided into four categories: large-grain species (Coffe aliberica), medium-grain species (Coffearobusta), small-grain species (Coffea arabica), and excelsa species (Coffea excelsa). Among them, the coffee beans of the small-grain species have the best quality. Coffee is the most commonly used beverage plant and has great economic value. my country first introduced coffee trees to Taiwan for planting in 1884. Hainan and Yunnan are currently the main coffee producing areas in my country. Traditional Chinese medicine believes that coffee is slightly bitter, astringent, and flat; it has the effects of refreshing, diuretic, and stomachic, and is mainly used to treat mental fatigue and loss of appetite. Coffee contains a variety of chemical components such as alkaloids, flavonoids, phenolic acids, and terpenes. It has the effects of lowering blood sugar, lowering blood lipids, anti-oxidation, and protecting nerves. It has great medicinal value and broad development prospects.

[0093] Golden Sophora japonicum is an excellent cultivar cultivated from the legume plant Sophora japonicum, named for its golden color of Sophora japonicum beans. Sophora japonicum beans are the dried flowers and buds of the legume plant Sophora japonicum (L.). The application of Sophora japonica was first recorded in "Shennong's Herbal Classic", which listed Sophora japonica fruit as a top-grade product. "Rihuazi Bencao" first recorded Sophora japonica flower as a medicine: "It can treat five types of hemorrhoids, heart pain, red eyes, kill abdominal worms and heat, treat skin wind, intestinal wind and bloody diarrhea, and red and white dysentery." Kou Zong of the Song Dynasty first clarified the harvesting of Sophora japonica rice in "Bencao Yanyi": "Harvest before it blooms... It is very good for treating intestinal wind and heat, and bloody diarrhea, but do not overdose." Sophora japonica rice, Sophora japonica flower and Sophora japonica fruit were included in the catalogue of food and medicine in 2002. The flavonoids contained in Sophora japonica rice, which are food and medicine, have very high medicinal and nutritional value to the human body. Both medicines taste bitter and are cold in nature. They enter the liver and large intestine meridians, and have the effects of cooling blood and stopping bleeding, clearing the liver and purging fire. They are mainly used for blood-heat bleeding, blood in the stool and hemorrhoids, red eyes and headaches and other diseases.

[0094] In golden locust coffee, the main effects of golden locust on the human body are: softening blood vessels, increasing blood vessel elasticity, preventing capillary rupture, clearing and cooling blood, anti-bacterial and anti-inflammatory, repairing and regenerating, improving digestion, detoxifying and beautifying, improving immunity, and delaying aging. Coffee has anti-inflammatory and lipid-lowering effects. The two work together to prevent and treat dyslipidemia, which is an effective preventive measure. Golden locust coffee is also a high-quality health product that can be widely promoted and has a good prospect.

[0095] Modern pharmacology shows that coffee is a complex mixture of thousands of chemical substances. The most important plant alkaloid is caffeine, which is a xanthine alkaloid compound and a central nervous system stimulant. Coffee has the effect of lowering blood lipids. Paul F. Lebeau et al. mentioned in their study that caffeine intake can reduce the level of PCSK protein in the blood. PCSK9 is a protein that is mainly expressed in the liver and secreted into the blood. This protein can reduce the liver's ability to process excess low-density lipoprotein (LDL) cholesterol. LDL cholesterol in the blood is an important indicator of cardiovascular disease risk. When the level of PCSK protein decreases or its activity is inhibited, the LDL receptors on the surface of liver cells will quickly remove excess LDL cholesterol in the blood. In this study, cell experiments and animal experiments further proved that caffeine (CF) reduces the expression and secretion of PCSK9 by antagonizing the de novo synthesis of PCSK9. It can increase the level of Ca2+ in the endoplasmic reticulum (ER) of the liver, block the transcriptional activation of SREBP2 responsible for regulating PCSK9, and thus increase the expression of LDLR and the clearance of LDLc. MingDing et al. analyzed 36 prospective cohort studies on the relationship between coffee drinking and cardiovascular disease risk, and concluded that moderate coffee drinking can reduce the risk of cardiovascular disease, people who drink 3 to 5 cups of coffee a day have the lowest risk of cardiovascular disease, and heavy coffee drinking is not associated with cardiovascular disease risk.

[0096] Coffee also has anti-inflammatory effects. Caffeine can reduce inflammatory responses, has antioxidant effects, reduces the activity of NF-κB, a key factor associated with inflammation, and negatively affects the production of proinflammatory cytokines by affecting adenosine receptors. Studies by Sara Martínez-López et al. showed that in healthy subjects, after caffeine intervention, root cytokines IL-1β, IL-6, and TNF-α tended to decrease, while in participants with hypercholesterolemia, these cytokines did not change. Anti-inflammatory markers IL-4, IL-10, and IL-13 tended to decrease in healthy subjects.

[0097] The ingredients such as rutin (rutin) and quercetin (aglycone quercetin) in golden sophora have good effects of cooling blood and stopping bleeding. Rutin has a vitamin P-like effect, can reduce capillary permeability and fragility, promote cell proliferation and prevent blood cell aggregation, as well as anti-inflammatory, anti-allergic, diuretic, antispasmodic, antitussive, and lipid-lowering effects. It can be used as a therapeutic drug and a health product. It is mainly used clinically for the auxiliary treatment and prevention of hypertension, and can also be used to prevent and treat other bleeding diseases caused by rutin deficiency, such as preventing and treating cerebral vascular hemorrhage, hypertension, retinal hemorrhage, purpura, acute hemorrhagic nephritis, chronic tracheitis, abnormal blood osmotic pressure, and restoring capillary elasticity. It is also effective in preventing and treating diabetes and hyperlipidemia. Flavonoids can maintain the normal tension of capillaries, reduce their permeability, restore the normal elasticity of capillaries that have increased fragility and bleeding, dilate coronary blood vessels, improve myocardial circulation, enhance the contractility and output of the heart, and reduce heart rate; in addition, it has anti-inflammatory, antispasmodic, anti-ulcer effects, and inhibits bacteria, fungi and viruses.

[0098] In the previous study, the article "Effect of Golden Sophora Refined Powder on Vascular Endothelial Peroxidation and Inflammatory Response in Rats with Hyperlipidemia" of this application has been published. Long-term HLP can damage the function of vascular endothelium, activate inflammatory mediators, and cause inflammatory response. At the same time, the excessive release of inflammatory mediators opens the inflammatory cascade, accelerates the accumulation of lipids in blood vessels, further aggravates the damage of vascular endothelium, and thus forms atherosclerosis. Therefore, under the continuous HLP state, it is necessary not only to directly treat hyperlipidemia, but also to indirectly reduce the level of inflammatory response. Through the specific analysis of inflammatory mediator indicators and the comparison of changes in the model group and the normal group, it is shown that HLP can cause the high expression of the above-mentioned inflammatory mediators in blood vessels, which may be related to the vascular endothelial damage caused by HLP; the results show that Golden Sophora Refined Powder can play its vascular protective role by reducing the high expression of inflammatory mediators in inflammatory response.

[0099] Propylene glycol (MDA) is the final product of lipid peroxidation in the body and one of the classic indicators reflecting the level of oxidative stress in the body. As an important marker of cell membrane lipid peroxidation, it appears in large quantities in a high-fat state, thus reflecting the degree of peroxidation and cell damage in the body. Superoxide dismutase (SOD) is an antioxidant enzyme that removes superoxide anions in the human body. It has a certain specificity and can remove excess free radicals in the body to achieve an antioxidant effect. After the model was successfully established, the SOD content in the blood vessels of HLP rats decreased, causing the MDA level to rise in reverse, indicating that the antioxidant capacity in the blood vessels of HLP rats was reduced, the ability to remove free radicals in the body was reduced, and the inflammatory response was continuously activated, further aggravating the damage to the vascular endothelium; after treatment, the SOD activity increased and the MDA level decreased, indicating that the refined powder of golden acacia can remove free radicals, resist lipid oxidation, and has a certain protective effect on blood vessels.

[0100] Therefore, it has been proven that golden sophora refined powder can effectively fight against vascular inflammation and peroxidation caused by hyperlipidemia, so as to protect the body.

[0101] This application focuses on the hyperlipidemia population. First, a randomized double-blind experiment is conducted to provide a higher level of clinical evidence for the efficacy and safety of Golden Sophora coffee in treating hyperlipidemia. Then, animal experiments are conducted to explore the mechanism of action of Golden Sophora coffee in treating hyperlipidemia. This provides a theoretical basis for the wider application of Golden Sophora coffee.

[0102] The working principle of the present invention is: the present application combines coffee and golden locust, and the medicine and food are of the same origin, achieving the effect of effective lipid reduction. The conventional lipid-lowering scheme currently used is to use statins, but long-term use of statins is prone to adverse reactions such as myalgia, myositis, new-onset diabetes, and abnormal liver function, which limits the clinical application of the drug. At the same time, the current clinical use of statins requires LDL-C ≥ 4.1mmol / L, but many patients have a slight increase in LDL-C and do not meet the drug intervention standard. Such patients can only control blood lipids by adjusting the diet structure, but the use of golden locust coffee can effectively reduce lipids while adjusting the diet structure, and there are almost no side effects, and it can be used for a long time, which can reduce the risk factors for hyperlipidemia. Coffee not only has a lipid-lowering effect, but modern medical research shows that habitual intake of coffee can reduce all-cause mortality by lowering heart rate, and golden locust coffee uses high-quality golden locust and pure Yunnan small-grain coffee, which can ensure a mellow and rich taste, and is easy for patients to adhere to taking.

[0103] At the same time, the innovative combination of golden locust and coffee utilizes the effect of regulating lipid metabolism to achieve the clinical effect of lowering blood lipids and reduce the risk factors of hyperlipidemia. Medicine and food have the same origin and almost no side effects, making this product safer and can be used for a long time. It also has a good preventive and conditioning effect on people with mild hyperlipidemia.

[0104] What is described above is only a preferred specific implementation manner of the present invention, but the protection scope of the present invention is not limited thereto. Any technician familiar with the technical field can make equivalent replacements or changes according to the technical scheme and inventive concept of the present invention within the technical scope disclosed by the present invention, which should be covered by the protection scope of the present invention.

Claims

1. A Chinese medicinal beverage for protecting liver and reducing lipids, characterized in that: Including drinks, the drinks contain golden locust, coffee and distilled water, the coffee requires 18g, the golden locust requires 8g, the distilled water requires 275ml, and the amount of the drinks used is increased or decreased according to the proportion.

2. A Chinese medicinal beverage for protecting liver and reducing lipids according to claim 1, characterized in that: The golden acacia is refined into golden acacia refined powder by freeze-crushing technology, and the coffee is made into coffee powder by cold extraction process.

3. The method for producing a liver-protecting and lipid-lowering Chinese medicinal beverage according to claim 2, characterized in that: include Step S1: prepare 18g of golden acacia powder and 8g of coffee powder, add 275ml of distilled water and mix; Step S2: placing the mixed solution into a vacuum distiller for distillation at 55° C.; Step S3: distill until the solution is concentrated to 1 g / ml golden acacia coffee concentrate.

Images